Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Tissue Repair

BPC-157 + KPV

Gut healing blend; gut-repair stack

Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend

This BPC-157 + KPV entry draws on 3 cited sources published 2008 to 2021. The evidence available is graded Anecdotal + Animal Studies on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend
Drug class
Tissue Repair
Structure
Co-formulated vial: BPC-157 (15-aa GEPPPGKPADDAGLV) + KPV (tripeptide Lys-Pro-Val, the C-terminal alpha-MSH fragment)
Route
SC / Oral
Half-life
BPC-157 less than 30 min (IV and IM, animal data); KPV ~minutes (rapid clearance)
Evidence tier
Anecdotal + Animal Studies
Availability
Compounding Restricted

Mechanism of action

BPC-157 promotes angiogenesis (VEGFR2), stabilises gut barrier function, and accelerates epithelial repair; KPV exerts NF-kB-suppressing anti-inflammatory activity at the colonic mucosa via melanocortin pathway intermediates. Layered: BPC-157 drives repair while KPV damps the inflammatory signal that delays it.

Reported areas of research

Gut mucosal repair; inflammatory bowel symptom support; intestinal-barrier restoration; combined healing + anti-inflammatory action commonly stacked for leaky-gut/IBD anecdotal protocols

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

250-500 mcg BPC-157 + 500-1000 mcg KPV SC daily near area of concern, or oral compounded form 1-2x daily. Cycle 4-6 weeks on / 2-4 weeks off

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication

Compared with

BPC-157 + KPV has published head-to-head comparisons with 7 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for BPC-157 + KPV in research literature?

Published peptide research reports the following dosing approach for BPC-157 + KPV: 250-500 mcg BPC-157 + 500-1000 mcg KPV SC daily near area of concern, or oral compounded form 1-2x daily. Cycle 4-6 weeks on / 2-4 weeks off. This is a research reference, not a clinical recommendation.

How is BPC-157 + KPV administered in research?

BPC-157 + KPV is administered via the following routes in published studies: SC / Oral.

What is the reported half-life of BPC-157 + KPV?

The reported half-life of BPC-157 + KPV is BPC-157 less than 30 min (IV and IM, animal data); KPV ~minutes (rapid clearance).

Is BPC-157 + KPV FDA-approved?

No. BPC-157 + KPV is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.

What level of evidence supports BPC-157 + KPV?

The current evidence base for BPC-157 + KPV is best characterised as: Anecdotal + Animal Studies. See the methodology page for the full evidence-tier rubric.

What side effects are reported for BPC-157 + KPV?

Known concerns reported in the literature for BPC-157 + KPV include: Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication. Always consult a qualified clinician before any human use.

Is there anyone who should not use BPC-157 + KPV?

No formal contraindications are established for BPC-157 + KPV, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication. Always consult a qualified clinician before any human use.

How does BPC-157 + KPV work?

The mechanism of action reported for BPC-157 + KPV in the literature: BPC-157 promotes angiogenesis (VEGFR2), stabilises gut barrier function, and accelerates epithelial repair; KPV exerts NF-kB-suppressing anti-inflammatory activity at the colonic mucosa via melanocortin pathway intermediates. Layered: BPC-157 drives repair while KPV damps the inflammatory signal that delays it..

What is BPC-157 + KPV studied for?

BPC-157 + KPV has been studied in the published literature for: Gut mucosal repair; inflammatory bowel symptom support; intestinal-barrier restoration; combined healing + anti-inflammatory action commonly stacked for leaky-gut/IBD anecdotal protocols. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is BPC-157 + KPV?

BPC-157 + KPV is classified as: Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend. Also known as: Gut healing blend; gut-repair stack.

Drug class

Research focus area

All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.

Primary sources

  1. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — review of pharmacology. Curr Pharm Des 2018. PMID 29804522
  2. Dalmasso G et al. KPV: a novel anti-inflammatory peptide derived from alpha-MSH inhibits epithelial pro-inflammatory pathways. Gastroenterology 2008. PMID 18054553
  3. Seiwerth S et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol 2021. PMID 34267654

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…